Department of Microbiology and Immunology, Faculty of Pharmacy, Mansoura University, Egypt.
J Infect Dis. 2019 Apr 16;219(9):1439-1447. doi: 10.1093/infdis/jiy678.
Emergence of multidrug-resistant (MDR) bacterial infections is a major problem in clinical medicine. Development of new strategies such as phage therapy may be a novel approach for treatment of life-threatening infections caused by MDR bacteria. A newly isolated phage, MMI-Ps1, with strong lytic activity was used for treatment of acute lung infection with Pseudomonas aeruginosa in a mouse model. Intranasal administration of a single dose of MMI-Ps1 immediately after infection provided a significant level of protection and increased the survival duration. Moreover, treatment of infected mice with phage as late as 12 hours after infection was still protective. Our in vitro results are the first to show the synergistic elimination of serum-resistant Pseudomonas strains by phage and complement. Phage therapy increases the efficacy of complement-mediated lysis of serum-resistant P. aeruginosa strains, indicating the importance of an intact complement system in clearing Pseudomonas infection during phage therapy.
多药耐药(MDR)细菌感染的出现是临床医学中的一个主要问题。开发新策略,如噬菌体治疗,可能是治疗由 MDR 细菌引起的危及生命的感染的一种新方法。一种新分离的噬菌体,MMI-Ps1,具有很强的溶菌活性,用于治疗铜绿假单胞菌引起的急性肺部感染的小鼠模型。感染后立即给予单次剂量的 MMI-Ps1 鼻内给药可提供显著的保护水平并延长生存时间。此外,即使在感染后 12 小时给予感染小鼠噬菌体治疗仍具有保护作用。我们的体外结果首次表明噬菌体和补体协同消除血清耐药型铜绿假单胞菌。噬菌体治疗增加了补体介导的血清耐药型铜绿假单胞菌裂解的效果,表明在噬菌体治疗期间,完整的补体系统在清除铜绿假单胞菌感染方面的重要性。